미국 연구팀은 다양한 조직으로 분화하는 배아줄기세포 (배성간세포•ES세포)를 만드는 데 세계 최초로 성공했다고 미국 과학잡지 셀(cell) 전자판이 15일(현지시간) 전했다.
오리건건강과학대학의 다치바나 마사히토(立花眞仁) 연구원을 비롯한 연구팀은 셀에 기고한 논문을 통해 성인 여성에서 기증받은 난자에 다른 사람 피부세포의 핵을 넣은 '체세포 인간복제 기술'을 사용해 이 같은 배성간세포를 만들어냈다고 밝혔 다.
인간복제 배아줄기세포를 놓고선 서울대 수의대의 황우석 전 교수가 이끈 줄기세포 연구팀이 2004년 제작에 성공했다고 발표했지만 나중에 조작된 것으로 판명 났 다.
재생 의료를 실현할 수 있는 인간복제 배아줄기세포에 대한 연구는 2006년께 유 도만능줄기(iPS)세포가 등장하면서 열기가 식었다.
다치바나 연구원은 "이번에 만든 배아줄기세포는 iPS세포보다 유전적 결함이 적을 가능성이 크다"고 소개했다.
연구팀은 환자의 체세포를 이용하면 유전자가 같아 이식 때 거부반응을 일으키지 않는 치료용 조직을 만들 수 있다고 설명했다.
논문에 따르면 연구팀은 미국에 거주하는 23~31세 여성 9명이 기증한 난자 126 개를 사용했으며 대학윤리위원회의 연구 승인을 받았다.
배아줄기세포는 126개 난자 가운데 6개에서 성공적으로 생성됐으며 이들 난자 중 4개는 한 여성이 제공한 것이라고 논문은 전했다.
오리건건강과학대학은 2007년에는 원숭이 난자를 이용해 복제 배아줄기세포를 만들어 내기도 했다. (연합뉴스)
<관련 영문 기사>
Stem cells recovered from cloned human embryos
Scientists have finally recovered stem cells from cloned human embryos, a longstanding goal that could lead to new treatments for such illnesses as Parkinson‘s disease and diabetes.
A prominent expert called the work a landmark, but noted that a different, simpler technique now under development may prove more useful.
Stem cells can turn into any cell of the body, so scientists are interested in using them to create tissue for treating disease. Transplanting brain tissue might treat Parkinson’s disorder, for example, and pancreatic tissue might be used for diabetes.
But transplants run the risk of rejection, so more than a decade ago, researchers proposed a way around that: Create tissue from stem cells that bear the patient‘s own DNA, obtained with a process called therapeutic cloning.
If DNA from a patient is put into a human egg, which is then grown into an early embryo, the stem cells from that embryo would provide a virtual genetic match. So in theory, tissues created from them would not be rejected by the patient.
That idea was met with some ethical objections because harvesting the stem cells involved destroying human embryos.
Scientists have tried to get stem cells from cloned human embryos for about a decade, but they’ve failed. Generally, that‘s because the embryos stopped developing before producing the cells. In 2004, a South Korean scientist claimed to have gotten stem cells from cloned human embryos, but that turned out to be a fraud.
In Wednesday’s edition of the journal Cell, however, scientists in Oregon report harvesting stem cells from six embryos created from donated eggs. Two embryos had been given DNA from skin cells of a child with a genetic disorder, and the others had DNA from fetal skin cells.
Shoukhrat Mitalipov of the Oregon Health & Science University, who led the research, said the success came not from a single technical innovation, but from revising a series of steps in the process. He noted it had taken six years to reach the goal after doing it with monkey embryos.
Mitalipov also said that based on monkey work, he believes human embryos made with the technique could not develop into cloned babies, and he has no interest in trying to do that. Scientists have cloned more than a dozen kinds of mammals, starting with Dolly the sheep.
The new work was financed by the university and the Leducq Foundation in Paris.
Dr. George Daley, a stem cell expert at Children‘s Hospital Boston who didn’t participate in the work, called the new results "one landmark step in a very long journey" toward creating DNA-matched transplant tissue.
Now, Daley said, scientists must compare the embryo-cloning approach with another technology that reprograms blood or skin cells directly into substitutes for embryonic stem cells. This reprogramming approach is technically simpler and doesn‘t involve embryos or require the donation of human eggs, and it was widely acclaimed when it was reported in 2007. Its Japanese developer shared a Nobel Prize last year.
But these substitute cells show some molecular differences compared to embryonic ones, which has led to questions about whether they can safely be used for treating patients. So it’s essential to compare the cells from the two methods, Daley said.
The new results mean "we have another tool," he said. "We have to learn more about this tool."
Daley said he believed scientists will prefer using the reprogramming approach unless it can be proven "beyond a shadow of a doubt" that embryo cloning produces better cells for treating patients.
Mitalipov said he believed his technique would present a particular advantage for treating patients with a certain type of rare diseases. These are caused by mutations in genes of the mitochondria, the power plants of cells. He noted his technique, unlike the cell-reprogramming approach, would supply tissue with new mitochondrial genes that could replace defective ones. Those new genes would come from the egg.
The Rev. Tad Pacholczyk, director of education for National Catholic Bioethics Center, an independent think tank in Philadelphia, reiterated his opposition to embryo cloning, calling the approach unethical.
"It involves the decision to utilize early human beings as repositories for obtaining desired cells," he said. "You‘re creating them only to destroy them.’‘
Marcy Darnovsky, executive director of the Center for Genetics and Society in Berkeley, California, said she was glad that Mitalipov doubted the embryos could be used to clone babies. She said the report still provides a good opportunity for the federal government to ban the use of cloning for reproduction. (AP)
